

FDA approves first oral hormone therapy for advanced prostate cancer

December 22 2020



Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. Food and Drug Administration announced Friday.

As opposed to currently approved hormone therapies that are injected or

placed as implants under the skin, Orgovyx is administered orally and works by blocking the [pituitary gland](#) from producing luteinizing hormone and follicle-stimulating hormone.

Researchers evaluated the safety and efficacy of Orgovyx in the phase 3 HERO study, a randomized, open-label trial in [prostate cancer patients](#) randomly assigned to either Orgovyx once a day or leuprolide injections every three months for 48 weeks. Among the 622 patients who received Orgovyx, 96.7 percent achieved and maintained castrate levels of testosterone (

Citation: FDA approves first oral hormone therapy for advanced prostate cancer (2020, December 22) retrieved 23 April 2024 from <https://medicalxpress.com/news/2020-12-fda-oral-hormone-therapy-advanced.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.